LUND, SWEDEN--(Marketwire - April 11, 2012) -
The Board of Directors of Active Biotech AB (publ) has issued a notice to
the
Annual General Meeting, which is to take place at 5 p.m. on Thursday, May
10, 2012, at Edison Park, Emdalavägen 16 in Lund, Sweden.
Please see the attached notification, which is being announced within short
in
Svenska Dagbladet and Post- och Inrikes Tidningar.
Lund, April 11, 2012
ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus
on autoimmune/inflammatory diseases and cancer. Projects in pivotal
phase are
laquinimod, an orally administered small molecule with unique
immunomodulatory
properties for the treatment of multiple sclerosis, TASQ for prostate
cancer and
ANYARA for use in cancer targeted therapy, primarily of renal cell
cancer. In
addition, laquinimod is in Phase II development for Crohn's and Lupus.
Further
projects in clinical development comprise the two orally administered
compounds,
57- 57 for Systemic Sclerosis as well as RhuDex® for RA.
Please visit
www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this
press
release in accordance with the Swedish Securities Market Act. This
information
was provided to the media for publication on April 11, 2012, at 8:30 a.m.
Notice of Annual General Meeting of Shareholders:
http://hugin.info/1002/R/1601111/505484.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1601111]
